Perspective Therapeutics, Inc. (NYSE:CATX) Given Average Recommendation of “Moderate Buy” by Brokerages

Perspective Therapeutics, Inc. (NYSE:CATX) has been given a consensus rating of “Moderate Buy” by the nine research firms that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 1-year price target among analysts that have covered the stock in the last year is $15.14.

Several equities research analysts recently commented on CATX shares. Wedbush reiterated an “outperform” rating and set a $11.00 price target on shares of Perspective Therapeutics in a research note on Friday. Bank of America cut shares of Perspective Therapeutics from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $24.00 to $5.00 in a research note on Monday, November 25th. UBS Group assumed coverage on shares of Perspective Therapeutics in a report on Thursday, October 24th. They issued a “buy” rating and a $20.00 price target on the stock. Oppenheimer cut their price target on Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating for the company in a report on Friday, November 22nd. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $16.00 price objective on shares of Perspective Therapeutics in a research note on Tuesday, January 14th.

Insider Transactions at Perspective Therapeutics

In related news, Director Heidi Henson acquired 25,975 shares of the company’s stock in a transaction on Wednesday, December 4th. The shares were purchased at an average price of $3.85 per share, for a total transaction of $100,003.75. Following the purchase, the director now owns 25,975 shares in the company, valued at $100,003.75. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Johan M. Spoor purchased 8,000 shares of Perspective Therapeutics stock in a transaction dated Wednesday, December 4th. The shares were purchased at an average price of $3.77 per share, with a total value of $30,160.00. Following the completion of the acquisition, the chief executive officer now owns 36,257 shares in the company, valued at $136,688.89. The trade was a 28.31 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders purchased a total of 67,570 shares of company stock valued at $256,789 in the last three months. 3.52% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Perspective Therapeutics

Several hedge funds have recently modified their holdings of CATX. Koa Wealth Management LLC bought a new stake in Perspective Therapeutics in the 4th quarter valued at $83,000. Wealth Effects LLC lifted its stake in shares of Perspective Therapeutics by 186.8% in the fourth quarter. Wealth Effects LLC now owns 38,000 shares of the company’s stock valued at $121,000 after buying an additional 24,750 shares during the period. SG Americas Securities LLC grew its position in Perspective Therapeutics by 41.3% during the fourth quarter. SG Americas Securities LLC now owns 26,088 shares of the company’s stock worth $83,000 after buying an additional 7,627 shares in the last quarter. Trueblood Wealth Management LLC raised its holdings in Perspective Therapeutics by 37.0% in the 4th quarter. Trueblood Wealth Management LLC now owns 22,236 shares of the company’s stock valued at $71,000 after acquiring an additional 6,000 shares in the last quarter. Finally, Taylor & Morgan Wealth Management LLC lifted its position in shares of Perspective Therapeutics by 86.7% in the 4th quarter. Taylor & Morgan Wealth Management LLC now owns 56,000 shares of the company’s stock worth $179,000 after acquiring an additional 26,000 shares during the period. 54.66% of the stock is owned by institutional investors.

Perspective Therapeutics Price Performance

Shares of NYSE:CATX opened at $4.01 on Friday. Perspective Therapeutics has a 52 week low of $2.70 and a 52 week high of $19.05. The company’s 50 day moving average is $3.68 and its two-hundred day moving average is $9.75.

Perspective Therapeutics (NYSE:CATX) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.21) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.21). The company had revenue of $0.37 million for the quarter. Perspective Therapeutics had a negative return on equity of 27.40% and a negative net margin of 4,096.66%. As a group, research analysts forecast that Perspective Therapeutics will post -0.88 earnings per share for the current year.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.